N-terminal propeptide of type 3 procollagen (PRO-C3) is a biomarker of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). This study examines the association between PRO-C3 concentration and liver fibrosis assessed by magnetic resonance elastography (MRE)-measured stiffness (MRE-stiffness) and the heritability of PRO-C3 concentration in a cohort of twins and families with and without NAFLD. We performed a cross-sectional analysis of a well-characterized prospective cohort of 306 participants, including 44 probands with NAFLD-cirrhosis and their 72 first-degree relatives, 24 probands with NAFLD without advanced fibrosis and their 24 first-degree relatives, and 72 controls without NAFLD and their 72 first-degree relatives. Liver steatosis was assessed by magnetic resonance imaging proton density fat fraction, and liver fibrosis was assessed by MRE-stiffness. Serum PRO-C3 was assessed by competitive, enzyme-linked immunosorbent assay. We assessed the familial correlation of PRO-C3 concentration, the shared gene effects between PRO-C3 concentration and liver steatosis and fibrosis, and the association between PRO-C3 concentration and genetic variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes. In multivariable-adjusted models including age, sex, body mass index, and ethnicity, serum PRO-C3 correlated strongly with liver fibrosis (r2 = 0.50, P < 0.001) and demonstrated robust heritability (h2 , 0.36; 95% confidence interval [CI], 0.07, 0.59; P = 0.016). PRO-C3 concentration and steatosis had a strong genetic correlation (shared genetic determination: 0.62; 95% CI, 0.236, 1.001; P = 0.002), whereas PRO-C3 concentration and fibrosis had a strong environmental correlation (shared environmental determination: 0.55; 95% CI, 0.317, 0.717; P < 0.001). PRO-C3 concentrations were higher in carriers of the TM6SF2 rs58542926-T allele compared with noncarriers: 15.7 (± 10.5) versus 10.8 (± 5.7) ng/L (P = 0.047). Conclusion: Serum PRO-C3 correlates with MRE-assessed fibrosis, is heritable, shares genetic correlation with liver steatosis and shares environmental correlation with liver fibrosis. PRO-C3 concentration appears to be linked to both fibrosis and steatosis and increased in carriers of the TM6SF2 rs58542926 risk allele.
N-terminal propeptide of type 3 procollagen (PRO-C3) is a biomarker of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). This study examines the association between PRO-C3 concentration and liver fibrosis assessed by magnetic resonance elastography (MRE)-measured stiffness (MRE-stiffness) and the heritability of PRO-C3 concentration in a cohort of twins and families with and without NAFLD. We performed a cross-sectional analysis of a well-characterized prospective cohort of 306 participants, including 44 probands with NAFLD-cirrhosis and their 72 first-degree relatives, 24 probands with NAFLD without advanced fibrosis and their 24 first-degree relatives, and 72 controls without NAFLD and their 72 first-degree relatives. Liver steatosis was assessed by magnetic resonance imaging proton density fat fraction, and liver fibrosis was assessed by MRE-stiffness. Serum PRO-C3 was assessed by competitive, enzyme-linked immunosorbent assay. We assessed the familial correlation of PRO-C3 concentration, the shared gene effects between PRO-C3 concentration and liver steatosis and fibrosis, and the association between PRO-C3 concentration and genetic variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes. In multivariable-adjusted models including age, sex, body mass index, and ethnicity, serum PRO-C3 correlated strongly with liver fibrosis (r2 = 0.50, P < 0.001) and demonstrated robust heritability (h2 , 0.36; 95% confidence interval [CI], 0.07, 0.59; P = 0.016). PRO-C3 concentration and steatosis had a strong genetic correlation (shared genetic determination: 0.62; 95% CI, 0.236, 1.001; P = 0.002), whereas PRO-C3 concentration and fibrosis had a strong environmental correlation (shared environmental determination: 0.55; 95% CI, 0.317, 0.717; P < 0.001). PRO-C3 concentrations were higher in carriers of the TM6SF2rs58542926-T allele compared with noncarriers: 15.7 (± 10.5) versus 10.8 (± 5.7) ng/L (P = 0.047). Conclusion: Serum PRO-C3 correlates with MRE-assessed fibrosis, is heritable, shares genetic correlation with liver steatosis and shares environmental correlation with liver fibrosis. PRO-C3 concentration appears to be linked to both fibrosis and steatosis and increased in carriers of the TM6SF2rs58542926 risk allele.
Authors: Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba Journal: Gastroenterology Date: 2018-04-13 Impact factor: 22.682
Authors: Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming Journal: Am J Transl Res Date: 2013-04-19 Impact factor: 4.060
Authors: Mette J Nielsen; Sanne S Veidal; Morten A Karsdal; Diana J Ørsnes-Leeming; Ben Vainer; Stephen D Gardner; Robert Hamatake; Zachary D Goodman; Detlef Schuppan; Keyur Patel Journal: Liver Int Date: 2014-10-29 Impact factor: 5.828
Authors: P Dongiovanni; S Stender; A Pietrelli; R M Mancina; A Cespiati; S Petta; S Pelusi; P Pingitore; S Badiali; M Maggioni; V Mannisto; S Grimaudo; R M Pipitone; J Pihlajamaki; A Craxi; M Taube; L M S Carlsson; S Fargion; S Romeo; J Kozlitina; L Valenti Journal: J Intern Med Date: 2017-12-27 Impact factor: 8.989
Authors: Rohit Loomba; Tanya Wolfson; Brandon Ang; Jonathan Hooker; Cynthia Behling; Michael Peterson; Mark Valasek; Grace Lin; David Brenner; Anthony Gamst; Richard Ehman; Claude Sirlin Journal: Hepatology Date: 2014-10-29 Impact factor: 17.425
Authors: Tae Gyu Oh; Susy M Kim; Cyrielle Caussy; Ting Fu; Jian Guo; Shirin Bassirian; Seema Singh; Egbert V Madamba; Ricki Bettencourt; Lisa Richards; Ruth T Yu; Annette R Atkins; Tao Huan; David A Brenner; Claude B Sirlin; Michael Downes; Ronald M Evans; Rohit Loomba Journal: Cell Metab Date: 2020-06-30 Impact factor: 27.287
Authors: Becky K Brisson; Daniel C Stewart; Chelsea Burgwin; David Chenoweth; Rebecca G Wells; Sherrill L Adams; Susan W Volk Journal: Matrix Biol Date: 2022-03-24 Impact factor: 10.447
Authors: Marie Boyle; Dina Tiniakos; Jorn M Schattenberg; Vlad Ratziu; Elisabetta Bugianessi; Salvatore Petta; Claudia P Oliveira; Olivier Govaere; Ramy Younes; Stuart McPherson; Pierre Bedossa; Mette J Nielsen; Morten Karsdal; Diana Leeming; Stuart Kendrick; Quentin M Anstee Journal: JHEP Rep Date: 2019-07-04